BIOXYTRAN, INC
Close on Oct 19, 2026
- Market cap
- $2.56M
- P/E (TTM)
- –
- Dividend yield
- –
About Bioxytran
Pharmaceutical Preparations, SIC 2834
Bioxytran, Inc. is a clinical-stage pharmaceutical company focused on developing platform technologies in glycovirology, hypoxia, and degenerative diseases. Utilizing carbohydrate drug design and Galectin inhibitors, the company works to eliminate viruses such as SARS-CoV-2 and address conditions associated with cellular degeneration and inflammation. Its operational structure includes specialized subsidiaries dedicated to viral disease therapeutics, prototyping manufacturing equipment, developing partially hydrolyzed guar gum derivatives, and safeguarding intellectual property.
The company operates through four wholly owned subsidiaries, including Pharmalectin India Pvt Ltd., which manages regional clinical research and trials and holds commercial rights in India. Bioxytran maintains its principal executive offices in Needham, Massachusetts. The enterprise focuses its developmental activities across these entities without commercial sales reported in the provided text.
Summary of the business section of Bioxytran's latest annual report, written by StockData.
Company profile
Company
- Legal name
- BIOXYTRAN, INC
- Founded
- 2008
- Headquarters
- Needham, MA
- Address
- C/O Bioxytran, Inc., 75 2nd Ave, Suite 605 Ste 605 02494
- Phone
- (617) 494-1199
- Employees
- 4, Dec 31, 2015
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Nevada
- Fiscal year ends
- December 31
- Auditor
- Fruci & Associates II, PLLC, Spokane, Washington
Stock & identifiers
- Ticker
- BIXT
- Exchange
- OTC
- Shares outstanding
- 115M, Aug 14, 2026
- Public float
- $9.33M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-30 reverse, Aug 22, 2018; 1-for-50 reverse, Apr 10, 2015; 1-for-50 reverse, Mar 9, 2015; 3-for-1, May 2, 2011
- SEC CIK
- 1445815
- EIN
- 26-2797630
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| David Platt | CEO, Director | 20,038,903 |
| Ola Soderquist | CFO | 13,976,456 |
| Michael Sheikh | CCO | 8,214,720 |
| Dale H. Conaway | Director | 379,177 |
| Anders Utter | Director | 372,580 |
| Alan M. Hoberman | Director | 210,000 |
| Radka Milanova | Director | 203,688 |
Employees
Headcount reported in annual reports
“As of December 31, 2015, the Company had four employees.”
Corporate history
Events identified from SEC filings